Current Report Filing (8-k)
November 08 2022 - 9:30AM
Edgar (US Regulatory)
0001782107
false
0001782107
2022-11-04
2022-11-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 8, 2022 (November 4, 2022)
Blue Water Vaccines Inc.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-41294 |
|
83-2262816 |
(State or other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
201 E. Fifth Street, Suite 1900 Cincinnati, Ohio |
|
45202 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (513) 620-4101
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class |
|
Trading Symbol(s) |
|
Name of Each Exchange on Which Registered |
Common Stock, par value $0.00001 per share |
|
BWV |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 5.02 Departure of Directors or Certain
Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Michael
Venerable
Effective as of November
4, 2022, Michael Venerable resigned as a member of the Board of Directors (the “Board”) of Blue Water Vaccines Inc. (the “Company”).
Mr. Venerable’s departure from the Board was not the result of any disagreement with management or the Board on any matter relating
to the Company’s operations, policies or practices.
Appointment of Vuk Jeremić
Effective as of November
4, 2022, the Board appointed Vuk Jeremić to serve as a member of the Board and a member of the Nominating and Corporate Governance
Committee of the Board and Compensation Committee of the Board.
Vuk Jeremić is the President
of the Center for International Relations and Sustainable Development (CIRSD), a global public policy think-tank, and Editor-in-Chief
of the quarterly magazine “Horizons – Journal of International Relations and Sustainable Development.” Since 2013, Mr.
Jeremić has operated Vuk Jeremić ent Consulting Agency Belgrade, through which he currently serves as a senior advisor to
a leading global private equity firm and to one of the largest cryptocurrency exchanges. He also serves on the Advisory Board of the NYSE-listed
technology special purpose acquisition company, Adit Edtech Acquisition Corp. (ADEX:U). In 2016, Mr. Jeremić participated in the
official election for United Nations (UN) Secretary-General. After six rounds of voting in the UN Security Council, he finished in the
second place, behind Mr. Antonio Guterres. In June 2012, Mr. Jeremić was directly elected by the majority of world’s nations
to be the President of the 67th session of the UN General Assembly. During his term in office, he played a leading role in steering the
UN towards the establishment of the Sustainable Development Goals (SDGs). Mr. Jeremić served as Serbia’s Minister of Foreign
Affairs from 2007 to 2012. In 2007, he chaired the Council of Europe’s Committee of Ministers. Mr. Jeremić has lectured at
major universities, think-tanks, and institutes around the world, as well as published opinion pieces in leading outlets including The
New York Times, The Washington Post, The Wall Street Journal, The Financial Times and Le Monde. Mr. Jeremić was named a Young Global
Leader by the World Economic Forum in 2013 and appointed to the Leadership Council of the UN Sustainable Development Solutions Network
(UN SDSN) in 2014. Mr. Jeremić served as the President of the Serbian Tennis Federation from 2011 to 2015. Mr. Jeremić holds
a bachelor’s degree in Theoretical and Experimental Physics from Cambridge University and a master’s degree in Public Administration
in International Development from Harvard University’s John F. Kennedy School of Government. Mr. Jeremić is well qualified
to serve on the Board as he brings decades of experience in operational and strategy advisement on a global scale for both private and
public companies.
No family relationships
exist between Mr. Jeremić and any other directors or executive officers of the Company. There are no transactions to which the
Company is or was a participant and in which Mr. Jeremić has a material interest subject to disclosure under Item 404(a) of Regulation
S-K.
Item 7.01 Regulation FD Disclosure.
On
November 8, 2022, the Company issued a press release announcing the appointment of Vuk Jeremić to the Board.
The full text of the press
release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated by reference in this Item 7.01.
The foregoing (including
Exhibit 99.1) is being furnished pursuant to Item 7.01 and will not be deemed to be filed for purposes of Section 18 of the Securities
and Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise be subject to the liabilities of that section, nor
will it be deemed to be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Blue Water Vaccines Inc. |
|
|
Date: November 8, 2022 |
/s/
Joseph Hernandez |
|
Joseph Hernandez
Chief Executive Officer |
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Blue Water Biotech (NASDAQ:BWV)
Historical Stock Chart
From Sep 2023 to Sep 2024